Evotec has launched its accelerated drug development service INDiGO. With the launch of INDiGO, Evotec’s capabilities are combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches.
INDiGO is a development solution that has been successfully executed by Evotec’s recent acquisition of Aptuit for several years, who are market leaders in providing high-value integrated drug discovery and development solutions. The INDiGO service has been proven to reduce the time and cost of pre-clinical drug development whilst delivering a high-quality data package for CTA/IND level regulatory filings.
INDiGO activities include:
- API manufacture, formulation development, clinical supply, safety assessment, DMPK, bioanalysis and biomarkers, and regulatory submission documents preparation.
- Evotec’s partners benefit from a single, integrated provider for all required functions and capabilities coupled with best-in-class project management and seasoned scientific leadership.
“Evotec’s INDiGO delivers to our partners a truly integrated approach to accelerate development of their drug candidates to regulatory submission in the most time- and cost-efficient manner. Our track record and expertise in combing the appropriate scientific knowledge with the right technical processes and project management ensures on time and budget delivery of clinic ready candidates,” Dr. Mario Polywka, Chief Operating Officer, said. “INDiGO allows our customers to seamlessly transition from candidate selection into the regulatory space and to patients efficiently and quickly.”